CA2884361C - Peptide antagonists of the vasopressin-2 receptor derived from a dendoaspis toxin - Google Patents

Peptide antagonists of the vasopressin-2 receptor derived from a dendoaspis toxin Download PDF

Info

Publication number
CA2884361C
CA2884361C CA2884361A CA2884361A CA2884361C CA 2884361 C CA2884361 C CA 2884361C CA 2884361 A CA2884361 A CA 2884361A CA 2884361 A CA2884361 A CA 2884361A CA 2884361 C CA2884361 C CA 2884361C
Authority
CA
Canada
Prior art keywords
seq
protein
amino acid
disease
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884361A
Other languages
English (en)
French (fr)
Other versions
CA2884361A1 (en
Inventor
Nicolas Gilles
Denis SERVENT
Loic Quinton
Helen REINFRANK
Ralph WITZGALL
Bernard Mouillac
Christiane MENDRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Liege
Universitaet Regensburg
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Universite de Liege
Universitaet Regensburg
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Liege, Universitaet Regensburg, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Universite de Liege
Publication of CA2884361A1 publication Critical patent/CA2884361A1/en
Application granted granted Critical
Publication of CA2884361C publication Critical patent/CA2884361C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2884361A 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor derived from a dendoaspis toxin Active CA2884361C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306120.2A EP2708235A1 (en) 2012-09-17 2012-09-17 Peptide antagonists of the vasopressin-2 receptor
EP12306120.2 2012-09-17
PCT/IB2013/058615 WO2014041526A1 (en) 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor

Publications (2)

Publication Number Publication Date
CA2884361A1 CA2884361A1 (en) 2014-03-20
CA2884361C true CA2884361C (en) 2022-03-22

Family

ID=46963639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884361A Active CA2884361C (en) 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor derived from a dendoaspis toxin

Country Status (14)

Country Link
US (1) US9631001B2 (enExample)
EP (2) EP2708235A1 (enExample)
JP (1) JP6392758B2 (enExample)
KR (1) KR102135954B1 (enExample)
CN (1) CN104684574B (enExample)
AU (1) AU2013316700B2 (enExample)
BR (1) BR112015005750B1 (enExample)
CA (1) CA2884361C (enExample)
DK (1) DK2895189T3 (enExample)
ES (1) ES2664747T3 (enExample)
MX (1) MX362664B (enExample)
NZ (1) NZ706202A (enExample)
RU (1) RU2015114320A (enExample)
WO (1) WO2014041526A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528476A (ja) * 2018-06-28 2021-10-21 サルアクア ダイアグノスティックス， インコーポレイテッド ハプトグロビン関連タンパク質と関係する組成物および方法
EP3929209A1 (en) 2020-06-24 2021-12-29 Commissariat à l'Energie Atomique et aux Energies Alternatives Vasopressin-2 receptor antagonist peptides and uses thereof
CN115820734B (zh) * 2022-11-11 2024-12-13 北京希诺谷生物科技有限公司 中枢性尿崩症疾病模型犬的建立方法
CN116425888B (zh) * 2023-04-24 2024-11-05 徐州医科大学 一种多肽tat-v2r1c及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2007019267A1 (en) 2005-08-03 2007-02-15 Mineuet Therapeutics Ltd. MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α
US8343760B2 (en) * 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides

Also Published As

Publication number Publication date
CN104684574A (zh) 2015-06-03
AU2013316700B2 (en) 2017-10-12
EP2708235A1 (en) 2014-03-19
KR20150070172A (ko) 2015-06-24
JP6392758B2 (ja) 2018-09-19
BR112015005750A8 (pt) 2018-04-17
BR112015005750B1 (pt) 2022-08-16
WO2014041526A1 (en) 2014-03-20
EP2895189A1 (en) 2015-07-22
CN104684574B (zh) 2018-08-31
RU2015114320A (ru) 2016-11-10
DK2895189T3 (en) 2018-04-16
CA2884361A1 (en) 2014-03-20
MX362664B (es) 2019-01-31
BR112015005750A2 (pt) 2017-12-12
KR102135954B1 (ko) 2020-07-21
JP2016500001A (ja) 2016-01-07
EP2895189B1 (en) 2018-01-10
US9631001B2 (en) 2017-04-25
AU2013316700A1 (en) 2015-04-09
US20150252086A1 (en) 2015-09-10
NZ706202A (en) 2018-06-29
MX2015003225A (es) 2015-11-16
ES2664747T3 (es) 2018-04-23

Similar Documents

Publication Publication Date Title
JP6321299B2 (ja) グルカゴン受容体アゴニスト
US9241967B2 (en) Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction
CN110074997A (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN101861334A (zh) 受体相关蛋白（rap）环肽
CA2884361C (en) Peptide antagonists of the vasopressin-2 receptor derived from a dendoaspis toxin
WO2013033636A2 (en) Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
Gleixner et al. [3H] UR-JG102–A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y4 Receptor
Fischer et al. Adrenomedullin disulfide bond mimetics uncover structural requirements for AM1 receptor activation
Wolf et al. The ring size of monocyclic ET‐1 controls selectivity and signaling efficiency at both endothelin receptor subtypes
KR20160075826A (ko) 중증 저혈당증의 치료를 위한 신규 화합물
JP7617958B2 (ja) バソプレシン２受容体アンタゴニストペプチド及びその使用
EP3280801B1 (en) Internalisation of human htra1 and cargo proteins into mammalian cells
WO2014068023A1 (en) Dpp8 and dpp9 peptide inhibitors
Richardson Design and evaluation of fluorescent and non-fluorescent bivalent ligands to explore their mode of action at neuropeptide Y receptors
WO2018017922A2 (en) Selective bfl-1 peptides
Bower Molecular Determinants of Amylin Receptor Agonism
WO2011132938A2 (ko) Gpcr에 특이적으로 결합하는 gpcr-bpb
Stornaiuolo et al. Deorphanization of Adhesion GPCRs overexpressed in Glioblastoma
Koduri Folding and maturation of lipoprotein receptors
WO2008098308A1 (en) Agents and methods for treatment of cell proliferative diseases and conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180823